logo
Share SHARE
FONT-SIZE Plus   Neg

Protalix Says FDA Extends Taliglucerase Alfa PDUFA Date To May 1, 2012

Protalix BioTherapeutics, Inc. (PLX) Tuesday said it has received notification from the U.S. Food and Drug Administration that the FDA has extended the Prescription Drug User Fee Act goal date of the New Drug Application for taliglucerase alfa to May 1, 2012, a three-month extension from the previous PDUFA date of February 1, 2012.

Taliglucerase alfa is the Company's proprietary plant cell expressed recombinant form of human Glucocerebrosidase, which is being developed for the treatment of Gaucher disease.

In November 2011, the Company submitted certain clinical information regarding taliglucerase alfa in response to an FDA request. This request related mainly to the presentation of select data provided in the NDA.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Stitch Fix, an online personal styling service, has filed for its initial public offering on Nasdaq, expecting to raise $100 million. The company, which was founded in 2011 by Katrina Lake, is reportedly seeking a valuation of up to $4 billion in the IPO. The proposed NASDAQ trading symbol is "SFIX". Play and entertainment company Hasbro, Inc. reported Monday higher profit in its third quarter, benefited by strong revenues in all regions. Both earnings and topline beat market estimates. The improvements were partly offset by negative impact of the Toys"R"Us bankruptcy in the U.S. and Canada. Looking ahead, the company projects higher revenues for the fourth quarter. Dutch consumer electronics giant Philips Electronics NV reported Monday lower attributable net income in its third quarter, while pre-tax income increased. Sales were flat on a reported basis, but grew 4 percent on a comparable basis mainly on growth in China. Further, the company said its outlook for 2017 remains unchanged despite ongoing global uncertainties.
comments powered by Disqus
Follow RTT